T-ROSS-II has been designed to conduct a new observational study to generate additional evidence on the use of tezepelumab in severe asthma patients in routine clinical practice in Spain after its launch.
This is an observational, multi-centre, retrospective, single-arm study in patients 12 years and older with severe asthma.
Approximately 400 patients meeting the study eligibility criteria will be included in the T-ROSS-II.
